1. In Vivo
  2. >>Deal-Making

2023’s Unpartnered Assets – Where Are They Now?

 
• By Lucie Ellis-Taitt and Edwin Elmhirst

Last year, In Vivo spotlighted some of biopharma’s most highly valued yet unpartnered assets. Now it’s time to see if deals have been struck and review how NPVs have changed.

Business concept illustration of a businessman being guided by a hand holding a flashlight uncovering arrow sign.
• Source: Shutterstock

For inclusion in 2023’s list, an asset had to be wholly owned, outside of clinical trial collaborations or small, regional tie-ups, and its developer unlikely to want to launch alone. The table was based on the net present value of the assets, as computed by Evaluate. In Vivo spotlighted 10 assets that could draw attention from dealmakers.

Reviewing the 2023 table, three assets have lost value, according to NPV analysis from Evaluate. These are: Ventyx Biosciences, Inc.’s VTX958, uniQure N.V.’s AMT-130 and ALX Oncology, Inc.’s evorpacept. Of these drugs, VTX958 has been the biggest casualty; Ventyx has suspended development in all indications.

More from Deal-Making

In Conversation: Sketching The Future Of Biotech Investment With Lilly Ventures

 
• By Jo Shorthouse

Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By David Wild

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

Deals In Depth: February 2025

 
• By Deanna Kamienski and Maureen Riordan

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Deals Shaping The Industry, February 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during February 2025. Data courtesy of Biomedtracker.

More from In Vivo

Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth

 
• By David Wild

From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.

Deals In Depth: February 2025

 
• By Deanna Kamienski and Maureen Riordan

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Therapeutic Or Cosmetic? Patent Strategies For Dual-Use Innovations

 
• By Mairi Rudkin

In the pharma and cosmetic sectors, innovation often arises from new uses for known compounds. While the compounds may not be patentable, their new applications can be. European law allows patents on substances used in medical methods, but not on the methods themselves.